ImmPACT Bio Announces FDA Clearance of IND Application for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis

ImmPACT Bio Announces FDA Clearance of IND Application for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis IMPT-514 is the first-and-only known CD19/CD20 CAR T-cell therapy in development for multiple sclerosis Dual CD19/CD20 targeting is designed to enable broad depletion of pathogenic autoimmune cells Initiation of Phase 1 dose exploration trial expected first half of […]